| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司前身赛诺有限由赛诺控股于2007年9月21日以货币出资发起设立，设立时注册资本为800万美元。2007年9月10日，天津经济技术开发区管理委员会出具了《关于外商独资成立赛诺医疗科学技术有限公司的批复》（津开批（2007）486号），同意赛诺有限设立。2007年9月11日，天津市人民政府向赛诺有限核发了《中华人民共和国外商投资企业批准证书》（批准号：商外资津外商字[2007]02101号）。2007年9月21日，天津市工商行政管理局核发了《企业法人营业执照》。 公司专注于高端介入医疗器械研发、生产、销售，产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。公司自主研发设计的、拥有国际知识产权的BuMA生物降解药物涂层冠脉支架系统是公司的核心产品。报告期内，公司BuMA支架及颅内球囊扩张导管等介入医疗器械的销售收入为公司收入主要来源，占同期收入95%以上。自成立以来，公司的主营业务及主要产品均未发生过变化。 公司建立了完整的采购、生产和营销体系。采购方面，公司对供应商的经营资质、质量体系、供货稳定性、售后服务和价格进行持续考察，并设有《合格供方名单》，确保供应商能够满足公司质量体系的规定要求。生产方面，公司根据销售计划制定生产计划，并与销售部门定期沟通，对计划适时调整；公司生产过程严格遵循各类适用的质量管理体系和质量管理规范的要求，保证产品的质量和生产效率。营销方面，公司在境内外均有销售，报告期内以经销模式为主。截至2018年末，公司合作经销商超过400家，产品销售覆盖全国30个省市的超过1,000家医院，其中超过600家医院为三级医院。 | ||||||||||||||||||||||||
| Main Business | 专注于高端介入医疗器械研发、生产、销售，产品管线涵盖心血管、脑血管、结构性心脏病等介入治疗重点领域。公司自主研发设计的、拥有国际知识产权的BuMA 生物降解药物涂层冠脉支架系统是公司的核心产品。 | ||||||||||||||||||||||||
| Legal Representative | 孙箭华 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 黄凯 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 022-59862999;010-82163261 | ||||||||||||||||||||||||
| Fax No | 010-82162787 | ||||||||||||||||||||||||
| Website | www.sinomed.com | ||||||||||||||||||||||||
| ir@sinomed.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 30/10/2019 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.100 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 2.000 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.420B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |